Lafutidine , ≥99% , 118288-08-7
CAS NO.:118288-08-7
Empirical Formula: C22H29N3O4S
Molecular Weight: 431.55
MDL number: MFCD00867520
EINECS: 601-513-8
Pack Size | Price | Stock | Quantity |
10MG | RMB103.20 | In Stock |
|
50MG | RMB343.20 | In Stock |
|
250MG | RMB1199.20 | In Stock |
|
1g | RMB3992.00 | In Stock |
|
others | Enquire |
PRODUCT Properties
Melting point: | 92.7-94.9° |
Boiling point: | 704.2±60.0 °C(Predicted) |
Density | 1.252±0.06 g/cm3(Predicted) |
storage temp. | Sealed in dry,Store in freezer, under -20°C |
Water Solubility | Insoluble in water |
solubility | DMF:5.0(Max Conc. mg/mL);11.59(Max Conc. mM) DMSO:48.67(Max Conc. mg/mL);112.77(Max Conc. mM) DMSO:PBS (pH 7.2) (1:10):0.09(Max Conc. mg/mL);0.21(Max Conc. mM) Ethanol:9.0(Max Conc. mg/mL);20.86(Max Conc. mM) |
form | powder to crystal |
pka | 13.13±0.46(Predicted) |
color | White to Orange to Green |
CAS DataBase Reference | 118288-08-7(CAS DataBase Reference) |
Description and Uses
Lafutidine is a histamine H2 receptor antagonist with gastroprotective activity. It inhibits histamine-induced cAMP production in CHO cells expressing human histamine H2 receptors when used at a concentration of 10 nM. Intragastric administration of lafutidine (3, 10, and 30 mg/kg) reduces hemorrhagic esophageal lesion size and gastric acid secretion in a rat model of pyloric ligation-induced reflux esophagitis. It prevents 5-fluorouracil-induced intestinal mucositis, diarrhea, and body weight loss in wild-type, but not Trpv1-/- or sensory deafferented, mice when administered at doses ranging from 3 to 30 mg/kg. Lafutidine (10 mg/kg) also reduces indomethacin-induced antral ulcer size in wild-type, but not chemically-deafferented, rats.
Lafutidine, a newly developed histamine H(2)-receptor antagonist, inhibits gastric acid secretion
Safety
Symbol(GHS) | GHS07 |
Signal word | Warning |
Hazard statements | H302-H315-H319-H335 |
Precautionary statements | P261-P305+P351+P338 |
Safety Statements | 24/25 |
HS Code | 29349990 |